...
首页> 外文期刊>Biomaterials >Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy
【24h】

Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy

机译:低密度脂蛋白偶联的N-琥珀酰壳聚糖纳米粒子共同递送siRNA和阿霉素用于肝细胞靶向治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Developing safe and effective carriers of small interference RNA (siRNA) is a significant demand for the systemic delivery of siRNA. In this study, low-density lipoprotein (LDL) was isolated from human plasma and loaded with cholesterol-conjugated siRNA to silence the multidrug resistant gene of tumors. Chol-siRNA/LDL-coupled N-succinyl chitosan nanoparticles loaded with doxorubicin (Dox-siRNA/LDL-SCS-NPs) were then prepared and characterised. The Dox-siRNA/LDL-SCS-NPs had average particle size of 206.4±9.2nm, entrapment efficiency of 71.06%±1.42%, and drug-loading amount of 12.35%±0.87%. Invitro antitumor activity revealed that cell growth was significantly inhibited. The accumulation of Dox by fluorescence microscopy and flow cytometry showed that LDL-coupled nanoparticles were more easily taken up than Dox-SCS-NPs. Results of confocal microscopy and reverse transcription-PCR revealed the highly efficient uptake of siRNA and the decrease in mdr1 mRNA expression. LDL-coupled nanoparticles protected siRNA from macrophage phagocytosis by dynamic observation using live cell station. Invivo tumor-targeting suggested that Cy7-labelled Dox-LDL-SCS-NPs were markedly accumulated in an analyzed in situ liver tumor model. Results indicated that LDL-SCS-NPs were effective tumor-targeting vectors and that the preparation form may provide a new strategy for co-delivering siRNA and antitumor drugs.
机译:开发小干扰RNA(siRNA)的安全有效载体是对siRNA全身递送的重大需求。在这项研究中,从人血浆中分离出低密度脂蛋白(LDL),并加入胆固醇偶联的siRNA,以沉默肿瘤的多药耐药基因。然后制备载有阿霉素的Chol-siRNA / LDL偶联的N-琥珀酰壳聚糖纳米颗粒(Dox-siRNA / LDL-SCS-NPs)。 Dox-siRNA / LDL-SCS-NPs的平均粒径为206.4±9.2nm,包封率为71.06%±1.42%,载药量为12.35%±0.87%。体外抗肿瘤活性显示细胞生长被显着抑制。通过荧光显微镜和流式细胞术对Dox的积累表明,与Dox-SCS-NP相比,LDL偶联的纳米颗粒更容易被吸收。共聚焦显微镜和逆转录PCR的结果表明,siRNA的高效摄取和mdr1 mRNA表达的降低。通过使用活细胞站的动态观察,LDL偶联的纳米颗粒可保护siRNA免受巨噬细胞吞噬作用。以体内肿瘤为靶标表明,Cy7标记的Dox-LDL-SCS-NPs在经过分析的原位肝肿瘤模型中明显积累。结果表明,LDL-SCS-NPs是有效的肿瘤靶向载体,该制剂形式可能为共同递送siRNA和抗肿瘤药物提供新的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号